Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
10 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
The company reported results for the period ended 31 May 2026 and said CEO Jerry Randall intends to retire from the role. It also highlighted revenue growth, a share buyback programme and recent disposals and acquisitions.
On Monday, Inventiva (NASDAQ: IVA ) discussed quarterly financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit The full earnings call is available at Summary Inventiva reported a strong financial position w
BeiGene (NASDAQ: ONC ) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered APIs. For comprehensive financial data and transcripts, visit View the webcast at Summary BeiGene reported strong Q2 2026 financial results with $1.7 billion in t
Recursion Pharmaceuticals (NASDAQ: RXRX ) reported second-quarter financial results on Wednesday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit Access the full call at Summary Recursion Pharma
John Wiley & Sons said Q1 Research publishing revenue rose 12%, while Learning revenue fell 20%. The company reiterated full-year guidance for mid-single-digit organic revenue growth, adjusted EPS of $4.60 to $5.05 and free cash flow of $205 million.
Jaguar Health released second-quarter 2026 financial results and held an earnings call, while highlighting its shift toward rare disease gastrointestinal programs and crofelemer development.
Milestone Scientific said second-quarter revenue rose 22% to $2.8 million, with medical segment revenue up 231% and 2026 revenue guidance reaffirmed at $9.8 million to $10.2 million.
Milestone Scientific (MLSS) reports financial results for its second quarter 2026, according to TradeXchange Newsdesk, with no additional figures provided in the feed.
Belite Bio said the FDA accepted its new drug application for tinlarebant with priority review and set a PDUFA date of February 12, 2027, while Q2 GAAP net loss widened to $28.4 million from $16.3 million.
On Tuesday, Lineage Cell Therapeutics (AMEX: LCTX ) discussed first-quarter financial results during its earnings call. The full transcript is provided below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. View the webcast at Summary Lineage Cell Therapeutics Inc rep